Venezuela Boosts Yellow Fever Vaccination Campaign With 1.3 Million Doses

Venezuela has received over 1.3 million doses of yellow fever vaccine to support a national vaccination campaign targeting individuals aged 1 to 59 in ten states, as confirmed by the Pan American Health Organization’s Revolving Fund procurement process.

The vaccines, purchased by the Venezuelan government for more than $2.3 million, are being deployed in response to yellow fever outbreaks detected in the country in 2026, with priority given to the states of Lara, Barinas, Portuguesa, and Aragua.

Health authorities have established more than 500 immunization points nationwide, including house-to-house vaccination teams and community clinics, to ensure broad access to the vaccine, which provides lifelong immunity with a single dose.

The yellow fever vaccine is a single-dose immunization that confers protection within ten days for most recipients and achieves 99% efficacy within one month, according to the World Health Organization, which recommends routine immunization in endemic regions.

In Greater Caracas, where no active circulation of yellow fever has been detected, key health districts have been activated to serve the population, including vaccination points in Catia, San Martín, El Valle, and La Urbina, as part of preparedness measures.

The ASIC Doctor Luis Razetti in Guárico state is intensifying outreach through the Luciérnaga Plan, deploying mobile teams and conducting educational sessions in schools, care centers, and public streets to promote vaccine acceptance and community protection.

Health officials emphasize that revaccination is not necessary, as a single dose provides durable, lifelong immunity, and they urge individuals traveling to or from prioritized areas to obtain the vaccine at least ten days in advance.

The acting president of Venezuela activated a national health contingency plan to prevent further spread following the detection of outbreaks in neighboring countries, coordinating with regional health authorities to strengthen surveillance and response capacity.

Yellow fever remains endemic in parts of South America and Africa, and while the vaccine is generally safe, rare adverse events include severe allergies in approximately eight per million doses and neurological complications in about four per million doses, according to established safety data.

Global health agencies warn that gains in controlling vaccine-preventable diseases like yellow fever are under threat from declining immunization rates, misinformation, and funding gaps, underscoring the importance of sustained vaccination efforts to prevent resurgence.